Skip to content
Close menu

SBRI HEALTHCARE

Search our Innovation Portfolio

Find a company

Search the SBRI Healthcare and NHS Cancer Programme Innovation Open call portfolio.

If you would like further information on any of the companies listed in the Directory please contact the SBRI Healthcare PMO by email sbri@lgcgroup.com or tel: +44 20 8843 8125.

We would be happy to make introductions to the companies or provide any further feedback you require.

At a glance

4
Companies funded
£2,792,776
Total funding

Directory search results

Oncascan

Project The development of the lymphocyte genome sensitivity (LGS) test for the diagnosis of cancer
Description

Oncascan is introducing a step change in cancer diagnosis and management. The patented Lymphocyte Genome Sensitivity (LGS) blood test uses increased sensitivity to ultra-violet induced DNA damage of lymphocytes from cancer patients to distinguish between those with and without the disease.

The project aims to develop a practical system for use in clinical laboratories to improve the management of patients with suspected cancers. Before embarking on invasive and costly investigations, patients found to not have cancer can be identified with the obvious reduction for them in anxiety, discomfort, time off work and clinical risk.

Funding £ 884,551
Competition Competition 5 - Improving Diagnosis and Treatment Management of Cancer
Competition Date September 2013
Health Innovation Network Partner Oxford AHSN

Astrimmune

Project Implementation and Validation of a novel test for pancreatic and other gastrointestinal cancers based on shed tumour cells in the blood
Description

Astrimmune is developing a diagnostic test for pancreatic and other gastrointestinal cancers based on detection and profiling of shed tumour cells in the blood. Requiring only 6ml of blood, the test provides unique insight into surface markers and gene expression of pancreatic cancer cells; isolating these cells from blood allows detection before metastasis can occur. Survival rates of pancreatic cancer could be improved dramatically if early detection were possible.

Funding £ 912,650
Competition Competition 5 - Improving Diagnosis and Treatment Management of Cancer
Competition Date September 2013
Categories Cancer , Oral & gastrointestinal
Health Innovation Network Partner East Midlands AHSN
Website https://uk.linkedin.com/company/astrimmune

Owlstone

Project Non-invasive Screening Device for Early Stage Lung Cancer
Description

Owlstone is developing a non-invasive screening device for early stage lung cancer utilizing breath diagnostics. As for most cancers, early diagnosis of lung cancer leads to better patient outcomes. The LuCID (Lung Cancer Indicator Detection) project will allow Owlstone’s existing chemical detection technology to be used to diagnose lung cancer, by measuring the trace chemicals present in the breath of lung cancer patients.

Funding £ 912,310
Competition Competition 5 - Improving Diagnosis and Treatment Management of Cancer
Competition Date September 2013
Health Innovation Network Partner Eastern AHSN
Website http://www.owlstonenanotech.com/

Subscribe

Subscribe to the SBRI Healthcare newsletter and receive the latest competition information & latest news updates.